Business Context and Reporting Period
Company: Oragenics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: November 10, 2017
Event Date: November 13, 2017
Context: The filing addresses the Company's status regarding NYSE American continued listing standards.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status.
Material Changes
- Listing Status: The NYSE American notified Oragenics, Inc. that it has regained compliance with the Exchange's continued listing standards.
- Monitoring: The Company is now subject to the Exchange's normal continued listing monitoring procedures.
Outlook, Risks, and Contingencies
- Future Noncompliance Risk: If the Company is determined to be noncompliant with any continued listing standards within 12 months of this notice, the Exchange will consider the relationship between the previous noncompliance and the new event.
- Potential Consequences: Appropriate actions for future noncompliance may include implementing truncated compliance procedures or immediately initiating delisting proceedings.
Investor Verification Checklist
- Verify the specific listing standard that was previously violated and the metric used to regain compliance (e.g., share price, shareholder equity, or market value).
- Review the attached Press Release (Exhibit 99.1) for details on the Company's plan to maintain compliance.
- Monitor upcoming quarterly reports to ensure the Company maintains the required financial thresholds to avoid truncated compliance procedures.